Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

T-VEC injections into melanoma lesions show significant response rate

Impact of cytotoxics on pregnancy needs to be better understood

First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

Genomic sequencing helps identify best candidates for adjuvant chemo in colorectal cancer

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early-stage HER2-positive breast cancer

First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer